205 related articles for article (PubMed ID: 33922732)
1. Genetic Determinants in a Critical Domain of NS5A Correlate with Hepatocellular Carcinoma in Cirrhotic Patients Infected with HCV Genotype 1b.
Alkhatib M; Di Maio VC; De Murtas V; Polilli E; Milana M; Teti E; Fiorentino G; Calvaruso V; Barbaliscia S; Bertoli A; Scutari R; Carioti L; Cento V; Santoro MM; Orro A; Maida I; Lenci I; Sarmati L; Craxì A; Pasquazzi C; Parruti G; Babudieri S; Milanesi L; Andreoni M; Angelico M; Perno CF; Ceccherini-Silberstein F; Svicher V; Salpini R; On Behalf Of Hirma Hepatocarcinoma Innovative Research MArkers And Fondazione Vironet C Hcv Virology Italian Resistance
Viruses; 2021 Apr; 13(5):. PubMed ID: 33922732
[TBL] [Abstract][Full Text] [Related]
2. Evolution of hepatitis C virus non-structural 5A gene in the progression of liver disease to hepatocellular carcinoma.
De Mitri MS; Cassini R; Bagaglio S; Morsica G; Andreone P; Marino N; Bernardi M
Liver Int; 2007 Oct; 27(8):1126-33. PubMed ID: 17845542
[TBL] [Abstract][Full Text] [Related]
3. Baseline Amino Acid Substitutions in the NS5A ISDR and PKR Binding Domain of Hepatitis C and Different Fibrosis Levels and Levels of Development of Hepatocellular Carcinoma in Patients Treated with DAAs.
Paolucci S; Piralla A; Novazzi F; Fratini A; Maserati R; Gulminetti R; Novati S; Barbarini G; Sacchi P; Silvestri A; Baldanti F
Viruses; 2020 Feb; 12(3):. PubMed ID: 32106574
[TBL] [Abstract][Full Text] [Related]
4. Identification of a duplicated V3 domain in NS5A associated with cirrhosis and hepatocellular carcinoma in HCV-1b patients.
Le Guillou-Guillemette H; Ducancelle A; Bertrais S; Lemaire C; Pivert A; Veillon P; Bouthry E; Alain S; Thibault V; Abravanel F; Rosenberg AR; Henquell C; André-Garnier E; Petsaris O; Vallet S; Bour JB; Baazia Y; Trimoulet P; André P; Gaudy-Graffin C; Bettinger D; Larrat S; Signori-Schmuck A; Saoudin H; Pozzetto B; Lagathu G; Minjolle-Cha S; Stoll-Keller F; Pawlotsky JM; Izopet J; Payan C; Lunel-Fabiani F
J Clin Virol; 2015 Aug; 69():203-9. PubMed ID: 26209408
[TBL] [Abstract][Full Text] [Related]
5. Association of amino acid variations in the NS5A and E2-PePHD region of hepatitis C virus 1b with hepatocellular carcinoma.
Hung CH; Chen CH; Lee CM; Wu CM; Hu TH; Wang JH; Yen YH; Lu SN
J Viral Hepat; 2008 Jan; 15(1):58-65. PubMed ID: 18088246
[TBL] [Abstract][Full Text] [Related]
6. Complex Association of Virus- and Host-Related Factors with Hepatocellular Carcinoma Rate following Hepatitis C Virus Clearance.
Akuta N; Suzuki F; Sezaki H; Kobayashi M; Fujiyama S; Kawamura Y; Hosaka T; Kobayashi M; Saitoh S; Suzuki Y; Arase Y; Ikeda K; Kumada H
J Clin Microbiol; 2019 Jan; 57(1):. PubMed ID: 30381417
[TBL] [Abstract][Full Text] [Related]
7. Viral etiology of hepatocellular carcinoma and HCV genotypes in Taiwan.
Lee CM; Hung CH; Lu SN; Wang JH; Tung HD; Huang WS; Chen CL; Chen WJ; Changchien CS
Intervirology; 2006; 49(1-2):76-81. PubMed ID: 16166793
[TBL] [Abstract][Full Text] [Related]
8. Polymorphisms of the core, NS3, and NS5A proteins of hepatitis C virus genotype 1b associate with development of hepatocellular carcinoma.
El-Shamy A; Shindo M; Shoji I; Deng L; Okuno T; Hotta H
Hepatology; 2013 Aug; 58(2):555-63. PubMed ID: 23281009
[TBL] [Abstract][Full Text] [Related]
9. Effect of Hepatitis C Virus Genotype 1b Core and NS5A Mutations on Response to Peginterferon Plus Ribavirin Combination Therapy.
Nakamoto S; Imazeki F; Arai M; Yasui S; Nakamura M; Haga Y; Sasaki R; Kanda T; Shirasawa H; Yokosuka O
Int J Mol Sci; 2015 Sep; 16(9):21177-90. PubMed ID: 26370958
[TBL] [Abstract][Full Text] [Related]
10. High amino acid variability within the NS5A of hepatitis C virus (HCV) is associated with hepatocellular carcinoma in patients with HCV-1b-related cirrhosis.
Giménez-Barcons M; Franco S; Suárez Y; Forns X; Ampurdanès S; Puig-Basagoiti F; Sánchez-Fueyo A; Barrera JM; Llovet JM; Bruix J; Sánchez-Tapias JM; Rodés J; Saiz JC
Hepatology; 2001 Jul; 34(1):158-67. PubMed ID: 11431747
[TBL] [Abstract][Full Text] [Related]
11. NS5A resistance-associated variants undermine the effectiveness of ledipasvir and sofosbuvir for cirrhotic patients infected with HCV genotype 1b.
Ogawa E; Furusyo N; Nomura H; Dohmen K; Higashi N; Takahashi K; Kawano A; Azuma K; Satoh T; Nakamuta M; Koyanagi T; Kato M; Shimoda S; Kajiwara E; Hayashi J;
J Gastroenterol; 2017 Jul; 52(7):845-854. PubMed ID: 27913920
[TBL] [Abstract][Full Text] [Related]
12. Characterization of a HCV NS5A protein derived from a patient with hepatoma.
Yeh CT; Chang MH; Shyu WC; Chang ML; Yang PY; Tsao ML; Lai HY
Biochem Biophys Res Commun; 2005 Feb; 327(2):516-22. PubMed ID: 15629144
[TBL] [Abstract][Full Text] [Related]
13. Duplication of the V3 domain in hepatitis C virus (1b) NS5A protein: Clonal analysis and physicochemical properties related to hepatocellular carcinoma occurrence.
Petsaris O; Vallet S; Le Guillou-Guillemette H; Veillon P; Gouriou S; Barbier G; Nousbaum JB; Saliou P; NKontchou G; Trinchet JC; Lunel-Fabiani F; Payan C
J Clin Virol; 2016 Jan; 74():19-25. PubMed ID: 26655076
[TBL] [Abstract][Full Text] [Related]
14. Naturally occurring resistance mutations to inhibitors of HCV NS5A region and NS5B polymerase in DAA treatment-naïve patients.
Paolucci S; Fiorina L; Mariani B; Gulminetti R; Novati S; Barbarini G; Bruno R; Baldanti F
Virol J; 2013 Dec; 10():355. PubMed ID: 24341898
[TBL] [Abstract][Full Text] [Related]
15. Direct-acting antivirals after successful treatment of early hepatocellular carcinoma improve survival in HCV-cirrhotic patients.
Cabibbo G; Celsa C; Calvaruso V; Petta S; Cacciola I; Cannavò MR; Madonia S; Rossi M; Magro B; Rini F; Distefano M; Larocca L; Prestileo T; Malizia G; Bertino G; Benanti F; Licata A; Scalisi I; Mazzola G; Di Rosolini MA; Alaimo G; Averna A; Cartabellotta F; Alessi N; Guastella S; Russello M; Scifo G; Squadrito G; Raimondo G; Trevisani F; Craxì A; Di Marco V; Cammà C;
J Hepatol; 2019 Aug; 71(2):265-273. PubMed ID: 30959157
[TBL] [Abstract][Full Text] [Related]
16. Hepatitis C virus NS5A protein interacts with beta-catenin and stimulates its transcriptional activity in a phosphoinositide-3 kinase-dependent fashion.
Milward A; Mankouri J; Harris M
J Gen Virol; 2010 Feb; 91(Pt 2):373-81. PubMed ID: 19846673
[TBL] [Abstract][Full Text] [Related]
17. Hepatitis C virus (HCV) genotypes and the influence of HCV subtype 1b on the progression of chronic hepatitis C in Korea: a single center experience.
Cho EJ; Jeong SH; Han BH; Lee SU; Yun BC; Park ET
Clin Mol Hepatol; 2012 Jun; 18(2):219-24. PubMed ID: 22893873
[TBL] [Abstract][Full Text] [Related]
18. Substitutions in interferon sensitivity-determining region and hepatocarcinogenesis after hepatitis C virus eradication.
Yasuda S; Ishigami M; Ishizu Y; Kuzuya T; Honda T; Hayashi K; Toyoda H; Kumada T; Hirooka Y; Goto H
J Gastroenterol Hepatol; 2018 Nov; 33(11):1904-1911. PubMed ID: 29744922
[TBL] [Abstract][Full Text] [Related]
19. Hepatitis C virus (HCV) genotypes in Spanish patients with HCV infection: relationship between HCV genotype 1b, cirrhosis and hepatocellular carcinoma.
López-Labrador FX; Ampurdanés S; Forns X; Castells A; Sáiz JC; Costa J; Bruix J; Sánchez Tapias JM; Jiménez de Anta MT; Rodés J
J Hepatol; 1997 Dec; 27(6):959-65. PubMed ID: 9453419
[TBL] [Abstract][Full Text] [Related]
20. Impact of NS5A sequences of Hepatitis C virus genotype 1a on early viral kinetics during treatment with peginterferon- alpha 2a plus ribavirin.
Dal Pero F; Tang KH; Gerotto M; Bortoletto G; Paulon E; Herrmann E; Zeuzem S; Alberti A; Naoumov NV
J Infect Dis; 2007 Oct; 196(7):998-1005. PubMed ID: 17763320
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
